DCM
MDGL icon

Driehaus Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Driehaus Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.1M Sell
110,960
-706
-0.6% -$337K 0.43% 73
2025
Q4 		$65M Sell
111,666
-4,308
-4% -$2.2M 0.44% 73
2025
Q3 		$53.2M Buy
+115,974
New +$43.3M 0.38% 83
2024
Q2 		– Sell
-50,709
Closed -$13.5M – 421
2024
Q1 		$13.5M Buy
+50,709
New +$11.9M 0.13% 205

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Driehaus Capital Management's MDGL Position: Q1 2026 in Review

Driehaus Capital Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 0.63% in Q1 2026, selling an estimated $337K and leaving 110,960 shares worth $58.1M. The position accounts for 0.43% of the portfolio, ranked #73.

Driehaus Capital Management first reported a position in MDGL in Q1 2024 and has held it in 4 quarters since. The position peaked at $65M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Driehaus Capital Management held 110,960 shares of Madrigal Pharmaceuticals worth $58.1M as of Q1 2026.
  • Driehaus Capital Management sold 706 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $337K.
  • Madrigal Pharmaceuticals made up 0.43% of Driehaus Capital Management's portfolio in Q1 2026, its #73 holding.
  • Driehaus Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 4 quarters since.
  • Driehaus Capital Management's Madrigal Pharmaceuticals position peaked at $65M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.